-
1
-
-
10944225166
-
Adalimumab: Human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibody
-
D.E. Baker Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibody Rev Gastroenterol Disord 4 2004 196 210
-
(2004)
Rev Gastroenterol Disord
, vol.4
, pp. 196-210
-
-
Baker, D.E.1
-
2
-
-
2442590862
-
New drugs for rheumatoid arthritis
-
N.J. Olsen, and C.M. Stein New drugs for rheumatoid arthritis N Engl J Med 350 2004 2167 2179
-
(2004)
N Engl J Med
, vol.350
, pp. 2167-2179
-
-
Olsen, N.J.1
Stein, C.M.2
-
3
-
-
4544317926
-
Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab
-
A.L. Chew, A. Bennett, C.H. Smith, J. Barker, and B. Kirkham Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab Br J Dermatol 151 2004 492 496
-
(2004)
Br J Dermatol
, vol.151
, pp. 492-496
-
-
Chew, A.L.1
Bennett, A.2
Smith, C.H.3
Barker, J.4
Kirkham, B.5
-
4
-
-
0035960624
-
Onset of multiple sclerosis associated with anti-TNF therapy
-
N.L. Sicotte, and R.R. Voskuhl Onset of multiple sclerosis associated with anti-TNF therapy Neurology 57 2001 1885 1888
-
(2001)
Neurology
, vol.57
, pp. 1885-1888
-
-
Sicotte, N.L.1
Voskuhl, R.R.2
-
5
-
-
0035674613
-
Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides
-
N. Mohan, E.T. Edwards, T.R. Cupps, P.J. Oliverio, G. Sandberg, and H. Crayton Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides Arthritis Rheum 44 2001 2862 2869
-
(2001)
Arthritis Rheum
, vol.44
, pp. 2862-2869
-
-
Mohan, N.1
Edwards, E.T.2
Cupps, T.R.3
Oliverio, P.J.4
Sandberg, G.5
Crayton, H.6
-
6
-
-
84855225857
-
-
Humira (adalimumab). Abbott Laboratories.
-
US Federal Drug Administration. Advisory committee briefing document. Humira (adalimumab). Abbott Laboratories. Available from: URL: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3930B1_02_A-Abbott-Humira.pdf. Accessed February 4, 2003.
-
Advisory Committee Briefing Document
-
-
-
7
-
-
11144331435
-
Etanercept treatment in corticosteroid-dependent myasthenia gravis
-
J. Rowin, M.N. Meriggioli, E. Tuzun, S. Leurgans, and P. Christadoss Etanercept treatment in corticosteroid-dependent myasthenia gravis Neurology 63 2004 2390 2392
-
(2004)
Neurology
, vol.63
, pp. 2390-2392
-
-
Rowin, J.1
Meriggioli, M.N.2
Tuzun, E.3
Leurgans, S.4
Christadoss, P.5
-
8
-
-
0035719745
-
Tumor necrosis factor and motoneuronal degeneration: An open problem
-
P. Ghezzi, and T. Mennini Tumor necrosis factor and motoneuronal degeneration: an open problem Neuroimmunomodulation 9 2001 178 182
-
(2001)
Neuroimmunomodulation
, vol.9
, pp. 178-182
-
-
Ghezzi, P.1
Mennini, T.2
-
9
-
-
3242716045
-
Efficacy of etanercept in the treatment of acute, severe sciatica: A pilot study
-
S. Genevay, S. Stingelin, and C. Gabay Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study Ann Rheum Dis 63 2004 1120 1123
-
(2004)
Ann Rheum Dis
, vol.63
, pp. 1120-1123
-
-
Genevay, S.1
Stingelin, S.2
Gabay, C.3
-
10
-
-
0037624699
-
Etanercept (Enbrel) therapy for chronic inflammatory demyelinating polyneuropathy
-
R.L. Chin, W.H. Sherman, H.W. Sander, A.P. Hays, and N. Latov Etanercept (Enbrel) therapy for chronic inflammatory demyelinating polyneuropathy J Neurol Sci 210 2003 19 21
-
(2003)
J Neurol Sci
, vol.210
, pp. 19-21
-
-
Chin, R.L.1
Sherman, W.H.2
Sander, H.W.3
Hays, A.P.4
Latov, N.5
-
11
-
-
0038721588
-
Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study
-
M.H. Weisman, L.W. Moreland, D.E. Furst, M.E. Weinblatt, E.C. Keystone, and H.E. Paulus Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study Clin Ther 25 2003 1700 1721
-
(2003)
Clin Ther
, vol.25
, pp. 1700-1721
-
-
Weisman, M.H.1
Moreland, L.W.2
Furst, D.E.3
Weinblatt, M.E.4
Keystone, E.C.5
Paulus, H.E.6
-
12
-
-
0033546665
-
TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study; The Lenercept multiple sclerosis study group and the University of British Columbia MS/MRI analysis group
-
The Lenercept Multiple Sclerosis Study Group TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study; the Lenercept multiple sclerosis study group and the University of British Columbia MS/MRI analysis group Neurology 53 1999 457 465
-
(1999)
Neurology
, vol.53
, pp. 457-465
-
-
-
13
-
-
0029751983
-
Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2
-
B.W. van Oosten, F. Barkhof, L. Truyen, J.B. Boringa, F.W. Bertelsmann, and B.M. von Blomberg Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2 Neurology 47 1996 1531 1534
-
(1996)
Neurology
, vol.47
, pp. 1531-1534
-
-
Van Oosten, B.W.1
Barkhof, F.2
Truyen, L.3
Boringa, J.B.4
Bertelsmann, F.W.5
Von Blomberg, B.M.6
-
14
-
-
0026532880
-
Revised estimate of the prevalence of multiple sclerosis in the United States
-
D.W. Anderson, J.H. Ellenberg, C.M. Leventhal, S.C. Reingold, M. Rodriguez, and D.H. Silberberg Revised estimate of the prevalence of multiple sclerosis in the United States Ann Neurol 31 1992 333 336
-
(1992)
Ann Neurol
, vol.31
, pp. 333-336
-
-
Anderson, D.W.1
Ellenberg, J.H.2
Leventhal, C.M.3
Reingold, S.C.4
Rodriguez, M.5
Silberberg, D.H.6
-
15
-
-
0025268954
-
A reappraisal of the epidemiology of multiple sclerosis in Olmsted County, Minnesota
-
D.R. Wynn, M. Rodriguez, W.M. O'Fallon, and L.T. Kurland A reappraisal of the epidemiology of multiple sclerosis in Olmsted County, Minnesota Neurology 40 1990 780 786
-
(1990)
Neurology
, vol.40
, pp. 780-786
-
-
Wynn, D.R.1
Rodriguez, M.2
O'Fallon, W.M.3
Kurland, L.T.4
-
16
-
-
0035464263
-
Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: By what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?
-
W.H. Robinson, M.C. Genovese, and L.W. Moreland Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 44 2001 1977 1983
-
(2001)
Arthritis Rheum
, vol.44
, pp. 1977-1983
-
-
Robinson, W.H.1
Genovese, M.C.2
Moreland, L.W.3
|